| Data indicate that (4-Chloro-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone and (4-bromo-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone inhibited cell growth through inhibition of both alpha-1 Na(+)/K(+)-ATPase (NAK) and Ras oncogene activity. | None |
| these results define a novel role for GLI1 in carcinogenesis acting as a downstream effector of oncogenic KRAS in the tumor microenvironment. | None |
| Subtle changes in the molecular nature of KRAS oncogene activating mutations occurring in tumour cells have a major impact on the vascular strategy devised providing with new insights on the role of KRAS mutations on angiogenesis. | None |
| HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. | None |
| Oncogenic K-Ras modulates expression and localization of catenin and HDAC proteins in Rat2 cells. | None |
| Detection of K-Ras oncogene using magnetic beads-quantum dots in microfluidic chip. | None |
| Effects of hypoxanthine substitution in peptide nucleic acids targeting KRAS2 oncogenic mRNA molecules: theory and experiment. | None |
| Oncogenic Kras-induces TSP-1 upregulation in a p53-dependent manner. | None |
| oncogenic KRAS activation in Apc-driven tumours results in the expansion of the CSCs compartment by increasing beta-catenin intracellular stabilization. | None |
| Interferon-mediated regulation of myc and Ki-ras oncogene expression in long-term-treated murine viral transformed cells. | None |
| Detection of K-ras oncogene from the human genomic DNA using ultrasonication and a quantum dots-based microfluidic chip. | None |
| RAS is the most frequently mutated oncogene in cancers. Isoprenylcysteine carboxylmethyltransferase (ICMT) methylates RAS and other CaaX-containing proteins. | None |
| Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. | None |
| Detection of the intracellular ras p21 oncogene product by flow cytometry. | None |
| PLC-gamma and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. | None |
| PLC-gamma and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. | None |
| Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-kappaB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells. | None |
| The proto-oncogene KRAS is targeted by miR-200c. | None |
| These findings reveal a novel, differential responsiveness of PP5-ERK1 and PP5-ERK2 interactions to select oncogenic Ras variants and also support a role for PP5.ERK complexes in regulating the feedback phosphorylation of PP5-associated Raf1. | None |
| KRAS requires S181 phosphorylation to manifest its oncogenic properties, implying that its inhibition represents a relevant target to attack KRAS-driven tumors. | None |